datopotamab deruxtecan
For the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment:
• Patients without known actionable genomic alterations previously treated with platinum-based chemotherapy in the advanced or metastatic setting and programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, either in combination or sequentially;
• Patients with actionable genomic alterations previously treated with prior platinum-based therapy and targeted therapy for the detected alteration.